Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Периндоприл – ингибитор ангиотензинпревращающего фермента с самой большой доказательной базой
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В форме литературного обзора изложена концепция подхода к лечению пациентов с артериальной гипертензией высокого риска, у которых применение ингибиторов АПФ является наиболее перспективным с позиции доказательной кардиологии. Одним из наиболее изученных препаратов является периндоприл. В статье приводятся данные по особым свойствам молекулы периндоприла, а также по возможности использования комбинаций периндоприла и индапамида, а также периндоприла и амлодипина для реализации их органопротективных свойств. В завершении предложен дифференцированный подход к использованию различных препаратов, содержащих периндоприл, по разным показаниям.
Ключевые слова: артериальная гипертензия, периндоприл, индапамид, амлодипин, органопротекция.
Ключевые слова: артериальная гипертензия, периндоприл, индапамид, амлодипин, органопротекция.
________________________________________________
In the form of the literature review we shows the concept of the treatment of high-risk hypertensive patients, who have been taking ACE inhibitors which application is the most advanced approach from the perspective of evidence-based cardiology. One of the most studied drugs is perindopril. The article deals with the data on the special properties of perindopril molecules, as well as on the possibilities of using perindopril and indapamide combination, as well as on usage of indapamide and amlodipine for the realization of protective mechanism. At the conclusion of the article we offered the differentiated approach to the usage of different drugs containing perindopril for different indications.
Key words: arterial hypertension, perindopril, indapamide, amlodipine, organoprotection.
Полный текст
Список литературы
1. Van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33: 2088–97.
2. Напалков Д.А. Терапия периндоприлом: органопротекция, а не только антигипертензивный эффект. Кардиология. 2012; 12: 80–3.
3. Ranadive SA, Chen AX, Serajuddin AT. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme inhibitors. Pharm Res 1992; 9 (11): 1480–6.
4. Ferrari R, Bertrand ME, Remme WJ et al. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial. Expert Rev Cardiovasc Ther 2007; 5 (6): 1037–46.
5. McQueen MJ, Lonn E, Gerstein HC et al. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab Invest Suppl 2005; 240: 143–56.
6. Borghi C, Bacchelli S, Esposti DD et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 1999; 12 (7): 665–72.
7. Heart Outcomes Prevention Evaluation Study Investigators: Effect of an angiotensin converting-enzyme inhibitor ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.
8. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
9. Bertrand ME, Fox KM et al. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: A subgroup analysis of the EUROPA trial. Arch Cardiovasc Dis 2009; 102 (2): 89–96.
10. Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
11. PREAMI: perindopril and remodelling in elderly with acute myocardial infarction: study rationale and design. Cardiovasc Drugs Ther 2000; 14 (6): 671–9.
12. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370 (9590): 829–40.
13. Beckett IS, Peters R, Fletcher AE, Staessen JA et al. for the HYVET study group. Treatment of hypertension in patients 80 years of age and older. N Engl J Med 2008; 358 (18): 1887–98.
14. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475–84.
15. Dahlöf B1, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895–906.
16. Напалков Д.А., Жиленко А.В. Современные подходы к комбинированной терапии артериальной гипертензии. Системные гипертензии. 2013; 10 (4): 44–9.
17. Bertrand ME. Perindopril/amlodipine combination: an optimal synergy for cardiovascular protection. Eur Heart J Suppl 2009; 11 (Suppl. E): E22–E25.
2. Напалков Д.А. Терапия периндоприлом: органопротекция, а не только антигипертензивный эффект. Кардиология. 2012; 12: 80–3.
3. Ranadive SA, Chen AX, Serajuddin AT. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme inhibitors. Pharm Res 1992; 9 (11): 1480–6.
4. Ferrari R, Bertrand ME, Remme WJ et al. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial. Expert Rev Cardiovasc Ther 2007; 5 (6): 1037–46.
5. McQueen MJ, Lonn E, Gerstein HC et al. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab Invest Suppl 2005; 240: 143–56.
6. Borghi C, Bacchelli S, Esposti DD et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 1999; 12 (7): 665–72.
7. Heart Outcomes Prevention Evaluation Study Investigators: Effect of an angiotensin converting-enzyme inhibitor ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.
8. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
9. Bertrand ME, Fox KM et al. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: A subgroup analysis of the EUROPA trial. Arch Cardiovasc Dis 2009; 102 (2): 89–96.
10. Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
11. PREAMI: perindopril and remodelling in elderly with acute myocardial infarction: study rationale and design. Cardiovasc Drugs Ther 2000; 14 (6): 671–9.
12. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370 (9590): 829–40.
13. Beckett IS, Peters R, Fletcher AE, Staessen JA et al. for the HYVET study group. Treatment of hypertension in patients 80 years of age and older. N Engl J Med 2008; 358 (18): 1887–98.
14. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475–84.
15. Dahlöf B1, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895–906.
16. Напалков Д.А., Жиленко А.В. Современные подходы к комбинированной терапии артериальной гипертензии. Системные гипертензии. 2013; 10 (4): 44–9.
17. Bertrand ME. Perindopril/amlodipine combination: an optimal synergy for cardiovascular protection. Eur Heart J Suppl 2009; 11 (Suppl. E): E22–E25.
Авторы
Д.А.Напалков
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
________________________________________________
D.A.Napalkov
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.